A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry

Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era

(2014) Samir Dalia et al.   ANNALS OF HEMATOLOGY

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

(2013) Z. Zhou et al.   BLOOD

Impact of Rituximab and Radiotherapy on Outcome of Patients With Aggressive B-Cell Lymphoma and Skeletal Involvement

(2013) Gerhard Held et al.   JOURNAL OF CLINICAL ONCOLOGY

Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study

(2013) Elisabeth Székely et al.   LEUKEMIA & LYMPHOMA

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

(2012) C. Muller et al.   BLOOD

Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study

(2012) Angelo M. Carella et al.   LEUKEMIA & LYMPHOMA

High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab

(2011) Francesco Gaudio et al.   ACTA HAEMATOLOGICA

Bulky disease has an impact on outcomes in primary diffuse large B-cell lymphoma of the breast: a retrospective analysis at a single institution

(2011) Suguru Fukuhara et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis

(2011) Jianhua Feng et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic in

(2010) Ranjana H. Advani et al.   BRITISH JOURNAL OF HAEMATOLOGY

Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan

(2010) Dai Chihara et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*

(2010) Sari Riihijärvi et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY

Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas

(2010) Takashi Watanabe et al.   LEUKEMIA & LYMPHOMA

Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy

(2009) M.-K. Song et al.   ANNALS OF ONCOLOGY

Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma

(2008) Luis F. Porrata et al.   AMERICAN JOURNAL OF HEMATOLOGY

Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma

(2008) M. Christina Cox et al.   BRITISH JOURNAL OF HAEMATOLOGY

Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab

(2008) Yasuhiro Oki et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Prognostic factors in patients with diffuse large B cell lymphoma: Before and after the introduction of rituximab

(2008) Lynette Ngo et al.   LEUKEMIA & LYMPHOMA

Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas

(2008) Dipti Talaulikar et al.   LEUKEMIA & LYMPHOMA